SOTERIA Collaborates with Tempus to Advance Precision Oncology for U.S. Military and Veterans Battling Cancer

(NASDAQ:TEM) Tempus and SOTERIA Precision Medicine Foundation announced a collaboration to deliver personalized, data-driven cancer treatment insights and advanced genomic sequencing to members of the U.S. active-duty and veteran military populations. The collaboration supports SOTERIA's Cancer Hunt™ initiative, which provides precision oncology patient navigation using Tempus' comprehensive genomic profiling and AI-enabled diagnostic platform. The initiative aims to help identify targeted therapies and clinical trial opportunities for active service members and veterans. SOTERIA facilitates CLIA-validated germline and somatic sequencing to ensure that each patient's care is informed by comprehensive molecular data when possible. Julia Civardi, Founder and CEO of SOTERIA, stated that the mission is to ensure patients have access to tools and technology that inform the most effective treatment path. Ezra Cohen, M.D., Chief Medical Officer of Oncology at Tempus, commented that collaborating with SOTERIA allows Tempus to provide cutting-edge genomic insights to clinicians and patients. CAPT Rob Newson, SEAL, USN (RET), PhD, Chief Community Officer at SOTERIA, emphasized the importance of the initiative for military families affected by cancer. The collaboration will streamline molecular profiling and data integration across SOTERIA's patient cohort. The partnership is intended to advance precision oncology research and optimize care pathways for military community members diagnosed with cancer. SOTERIA's Cancer Hunt™ initiative is highlighted as a key program in this collaboration. The announcement notes the increasing incidence of cancer at younger ages and advanced stages among military communities. The collaboration leverages Tempus' AI analytics and state-of-the-art genomic sequencing technology. The partnership is positioned as a means to turn complex molecular data into actionable treatment options for patients and care teams. The announcement provides links for more information about SOTERIA's Cancer Hunt™ Initiative and for scheduling a consult call with SOTERIA's nurse navigators.

Templeton Emerging Markets Inv Trust